Tofacitinib in rheumatology: From evidence to clinical practice

Speciality: Rheumatology

Description:

A warm welcome to all the medical professionals in this interesting session on Tofacitinib in rheumatology: From evidence to clinical practice
Tofacitinib, a Janus kinase (JAK) inhibitor, has emerged as a key treatment in rheumatology, particularly for conditions like rheumatoid arthritis (RA). Unlike traditional biologics, which target extracellular proteins, Tofacitinib works intracellularly by inhibiting JAK enzymes involved in inflammatory pathways. Clinical trials have demonstrated its efficacy in reducing joint inflammation, improving physical function, and halting disease progression in RA patients who have not responded to conventional therapies.
In clinical practice, Tofacitinib is often used as an alternative or adjunct to methotrexate or other biologics. It is available in an oral form, offering a convenient option for patients compared to injectable biologics. While highly effective, careful monitoring is required due to potential side effects, such as increased risk of infections. Tofacitinib has broadened the scope of treatment options in rheumatology, offering a novel approach to managing autoimmune diseases.
Therefore, get an overall knowledge of tofacitinib in rheumatology: from evidence to clinical practice. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars